Aflibercept for Treating Visual Impairment Caused by Macular Oedema after Branch Retinal Vein Occlusion (TA409)

Technology Appraisal Guidance No. 409

Source: National Institute for Health and Care Excellence

1. Guidance

1.1 Aflibercept is recommended as an option within its marketing authorisation for treating visual impairment in adults caused by macular oedema after branch retinal vein occlusion, only if the company provides aflibercept with the discount agreed in the patient access scheme.


    The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at

    This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

    © Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

    Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email:

    Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion

    Issue Date: September 2016

    Have you registered with us yet?

    Register now to enjoy more articles and free email bulletins

    Already registered?
    Sign in